CARE-MI
CARDIO REPAIR EUROPEAN MULTIDISCIPLINARY INITIATIVE
| Coordinatore | FUNDACION CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III
Organization address
address: C/ MELCHOR FERNANDEZ ALMAGRO 3 contact info |
| Nazionalità Coordinatore | Spain [ES] |
| Totale costo | 14˙939˙184 € |
| EC contributo | 11˙305˙102 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-04-01 - 2015-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III
Organization address
address: C/ MELCHOR FERNANDEZ ALMAGRO 3 contact info |
ES (MADRID) | coordinator | 1˙526˙627.11 |
| 2 |
CORETHERAPIX S.L
Organization address
address: PLAZA DE LA ENCINA 10 NUCLEO 1 PLANTA 3 contact info |
ES (MADRID) | participant | 1˙753˙119.00 |
| 3 |
InnoCore Technologies BV
Organization address
address: Kadijk 7D contact info |
NL (Groningen) | participant | 1˙088˙443.64 |
| 4 |
NANOMI BV
Organization address
address: ZUTPHENSTRAAT 51 contact info |
NL (OLDENZAAL) | participant | 1˙088˙443.64 |
| 5 | Nome Ente NON disponibile | ES | participant | 1˙086˙559.00 |
| 6 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 982˙731.00 |
| 7 |
LIVERPOOL JOHN MOORES UNIVERSITY
Organization address
address: Egerton Court Rodney Street 2 contact info |
UK (LIVERPOOL) | participant | 637˙956.64 |
| 8 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 497˙053.36 |
| 9 |
HLA ET MEDECINE
Organization address
address: Avenue Claude Vellefaux 1 contact info |
FR (Paris) | participant | 468˙080.00 |
| 10 |
INSTITUT CATALA DE LA SALUT
Organization address
address: GRAN VIA DE LES CORTS CATALANES 587 contact info |
ES (BARCELONA) | participant | 407˙746.00 |
| 11 |
INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA
Organization address
address: Av. da Republica, Quinta do Marques S/N contact info |
PT (OEIRAS) | participant | 377˙440.00 |
| 12 |
PROTEIN PRODUCTION SERVICES LTD
Organization address
address: Golda Meir St - Kiryat Weizmann Science Park 7 contact info |
IL (Ness Ziona) | participant | 343˙696.95 |
| 13 |
UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS
Organization address
address: Robert-Koch-Strasse 40 contact info |
DE (GOETTINGEN) | participant | 313˙200.00 |
| 14 |
UNIVERZA V LJUBLJANI
Organization address
address: KONGRESNI TRG 12 contact info |
SI (LJUBLJANA) | participant | 200˙446.80 |
| 15 |
VIVOTECNIA RESEARCH SL
Organization address
address: CALLE SANTIAGO GRISOLIA 2 contact info |
ES (TRES CANTOS - MADRID) | participant | 179˙861.00 |
| 16 |
FARMA-CROS IBERICA S.L.
Organization address
address: CASTILLA LA MANCHA. POLIGONO INDUSTRIAL CAMPORROSSO 7 contact info |
ES (ALBACETE) | participant | 173˙700.00 |
| 17 |
PHILIPS IBERICA SA
Organization address
address: CALLE MARIA DE PORTUGAL 1 contact info |
ES (MADRID) | participant | 111˙355.00 |
| 18 |
PHILIPS MEDICAL SYSTEMS NEDERLAND BV
Organization address
address: VEENPLUIS 4-6 contact info |
NL (BEST) | participant | 40˙159.00 |
| 19 |
VIB
Organization address
address: Rijvisschestraat 120 contact info |
BE (ZWIJNAARDE - GENT) | participant | 28˙484.66 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Ischemic Heart Disease (IHD) is the biggest single cause of death in Europe and in the developed world. Angioplasty and stents are successful in re-establishing perfusion of ischemic myocardium and have helped to reduce early mortality after acute myocardial infarction (AMI). However damaged tissue is not recovered and, therefore, this is always followed by cardiac remodelling and Chronic Heart Failure (CHF). CHF is a terminal disease with an annual mortality rate of ~18% with no cure besides heart transplantation, only available to a minority of patients. Autologous cell therapy has been proposed as a solution and clinically tested but has proven marginally effective at best. Its cost and the complexity of clinical procedures make it unsuitable for treating the large number of patients that need affordable and readily available products to treat the acute phase of the disease. Moreover, most of these approaches are predicated on the outmoded concept that the adult human myocardium lacks regenerative capacity. Recent findings show that adult myocardium harbours a population of resident pluripotent cells with the characteristics of true cardiac stem cells (CSC) able to regenerate contractile myocardium. This opens novel therapeutic avenues capable of producing real anatomical and functional regeneration. The CARE-MI proposal addresses the clinical implementation of this recent paradigmatic change. We will clinically test and further develop myocardial regenerative therapies based on the in situ activation, multiplication and differentiation of the endogenous CSCs with the aim to provide therapies that are: a)Affordable, in terms of the production costs of the medicinal product b)Readily and widely available, implying that the product may be easily stored and readied for application at all times at minimum cost. c)Easy to apply and compatible with current clinical standard of care for AMI, including the widespread use of PTCA interventions'